Palo Alto, CANCT04640987Now EnrollingIRB Ready

Hematologic Diseases Clinical Trial in Palo Alto, CA

Access cutting-edge hematologic diseases treatment through this phase 1 clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.

Sponsored by Porteus, Matthew, MD

Quick Self-Assessment

See if you qualify for this Palo Alto location

Preparing your pre-screening questions…

Expert Care in Palo Alto

Access hematologic diseases specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hematologic diseases treatment provided free

Apply for This Palo Alto Location

Check if you qualify for this hematologic diseases clinical trial in Palo Alto, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Palo Alto

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Palo Alto site if eligible
  4. 4Begin participation

About This Hematologic Diseases Study in Palo Alto

The purpose of this study is to determine the safety of a cell therapy, T-allo10, after αβdepleted-HSCT in the hopes that it will boost the adaptive immune reconstitution of the patient while sparing the risk of developing severe Graft-versus-Host Disease (GvHD). The primary objective of Phase 1a is to determine the recommended Phase 2 dose (RP2D) administered after infusion of αβdepleted-HSCT in children and young adults with hematologic malignancies. A Phase 1b extension will occur after dose escalation, enrolling at the RP2D for the T-allo10 cells determined in the Phase 1 portion to evaluate the safety and efficacy of infusion of T-allo10 after receipt of αβdepleted-HSCT. Additionally, Phase 1b aims to explore improvements in immune reconstitution. All participants on this study must be enrolled on another study: NCT04249830

Sponsor: Porteus, Matthew, MD

Who Can Participate

Inclusion Criteria

prior to enrollment:
1\. Age \> 1 months (with minimum weight of 10 Kg) and \< 45 years.
2\. Patients deemed eligible for allogeneic HSCT under the originating study, NCT 04249830
3\. Patients with life-threatening hematological malignancies for which HSCT has been recommended:
High-risk ALL in 1st CR, ALL in 2nd or subsequent CR;
High-risk AML in 1st CR, AML in 2nd or subsequent CR;
Myelodysplastic syndrome;
JMML (Juvenile myelomonocytic leukemia);
Non-Hodgkin lymphomas in 2nd or subsequent CR;
Other hematologic malignancies eligible for stem cell transplantation per institutional standard.
4\. All subjects ≥ 18 years of age must be able to give informed consent, or adults lacking capacity to consent must have a LAR available to provide consent. For subjects \<18 years old their LAR (i.e. parent or guardian) must give informed consent. Pediatric subjects will be included in age appropriate discussion and verbal assent will be obtained for those \> 7 years of age, when appropriate. Inclusion criteria prior to T-allo10 infusion:
Patient already received αβdepleted-HSCT and has myeloid engraftment.
Absence of active grade II aGvHD requiring \>0.5 mg/Kg of steroids or any diagnosis of grade III/IVaGvHD.

Exclusion Criteria

prior to MNC collection for Tallo-10 manufacturing.:
Not eligible to receive HSCT on NCT04249830
Received another investigational agent within 30 days of enrollment.
Pregnancy (positive serum or urine beta-HCG) within 7 days of MNC donation.
Patient or donor is not willing or able to undergo an additional non-mobilized apheresis for collection of MNC prior to donation of cells for participation in NCT04249830.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Palo Alto?

Yes, this clinical trial (NCT04640987) has an active research site in Palo Alto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hematologic Diseases Treatment Options in Palo Alto, CA

If you're searching for hematologic diseases treatment options in Palo Alto, CA, this clinical trial (NCT04640987) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Palo Alto research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced hematologic diseases specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hematologic diseases clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Palo Alto, CA

See all ankylosing spondylitis clinical trials recruiting in Palo Alto — not just this study.

Browse Ankylosing Spondylitis Trials in Palo Alto →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Palo Alto?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Palo Alto, CA